Create your personal agenda –check the favourite icon
Chair’s Opening Remarks
Keynotes
Meindert Boysen, Deputy Chief Executive and Director of the Centre for Health Technology Evaluation, National Institute for Health and Care Excellence
Future-proofing strategic & operational pricing?
Keynotes
Ana Plata, Global Head of Pricing, UCB
Keynote Panel Discussion: The impact of Covid-19 on Market Access and Pricing: Implications across Industry and the World, Lessons Learned and Results of the German EU-Presidency
Keynotes
Thomas Mueller, Head Of Directorate General 1 - Drugs, Medical Devices, Biotechnology, Federal Ministry of Health Germany
Tamir Singer, Head of Commercial Development, NHS England
Francis Arickx, Head Of The Directorate Reimbursement Of Medicines And Pharmaceutical Policy, Riziv-Inami
Anne Willemsen, Senior Project Manager, Joint Production Co-Lead Partner – Pharmaceuticals, Zorginstituut Nederland / EUnetHTA
Meindert Boysen, Deputy Chief Executive and Director of the Centre for Health Technology Evaluation, National Institute for Health and Care Excellence
Marco Rauland, Vice President Global Market Access & Pricing Strategic Planning, Merck Group
Sandro Cesaro-Tadic, Head Pricing I8 And Product Pricing Strategies, Roche
Hassan Bruneo, Head of Market Access, Pricing & Policy CEMEA, Alnylam Switzerland Gmbh
Panel Discussion: Making Real-World Evidence more useful for Regulatory Agencies and HTAs
RWE and Capability-building
Gilles Ducorroy, Head of RWE Services, Novartis
Erwin De Cock, Executive Director, Clinical Engagement, Syneos Health
Pier Paolo Olimpieri, Data Analyst Coordinator, Monitoring Registries Office, AIFA
Madhusudan Kabra, Director, Evidence Generation, Otsuka Pharmaceutical
Enkeleida Nikai, Head Of Real World Evidence, Senior Director At Janssen Europe, Middle East And Africa (Emea), Janssen Pharmaceutical
Anjan Chatterjee, Senior Vice President - Global Head, Medical Affairs, Insmed Incorporated
Elena Lungu, Manager Of Policy Development, Government of Canada
Antje Behring, Head of Pharmaceuticals Department, G-BA
Mario Ouwens, Group Director Medical & Payer Evidence Statistics, Astra Zeneca
Insight from industry: Value-based Contracting in the Netherlands
Pricing & Market Access
Jolanda Koenders, Head Of Patient Value And Access, Takeda
Exploring proposed financial models for gene therapies in ultra-rare diseases in South America
Rare Diseases
Marcelo Sal, Head of Market Access and Pricing, South Cone of South America, PTC Therapeutics
Is personalised medicine sustainable? What should be considered to ensure long term sustainability and access?
Rare Diseases
David Alderson, Director, Cogentia Healthcare Consulting
Selective contracting to improve patient access
Pricing & Market Access
Fabrizio Zucca, Director Market Access Dach, Intercept Pharmaceuticals Inc
Sustainability from a biotech perspective: Money never sleeps
Rare Diseases
Julien Patris, Country Manager Belgium & Luxembourg // Director Market Access & Policy CEMEA, Alnylam
Latest developments in RWE in Germany: Innovative & Legislative Considerations
RWE and Capability-building
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Kevin Rieger, Head Of Public And Governmental Affairs Dach, Ipsen Pharma Gmbh
Panel Discussion: Exploring International Reference Pricing for Pharmaceuticals and will this model succeed in the US?
Pricing & Market Access
Sylvie Greneche, Global Head of Market Access, General Medicines, Sanofi
Alex Bastian, Vice President, Value And Market Access, Galapagos NV
Juan Roman, Vice President, Global Market Access, HEOR and Pricing, Krystal Biotech
Bertrand Tardivel, General Manager, Frehel/ContrAST
Robert Orzechowski, Chief Operating Officer, Lancaster Cancer Centre
Jaime Espin, Professor, Andalusian School Of Public Health
Gustavo Saraiva Dos Anjos, Global Market Access Director For Biologics, GlaxoSmithKline
Erin Mistry, SVP, Head of Payer Strategy, Gov’t Affairs and Trade Relations, CorMedix Inc
Comparative overview of patient access to orphan drugs across Europe
Rare Diseases
Giovanni Tafuri, Director, International Pricing & Reimbursement and Policy Strategy, Apellis Pharmaceuticals
The use of registry data for HTA submissions and beyond
RWE and Capability-building
Helene Chevrou-Severac, HEOR Director, alexion
Insights from INESSS on the challenge of assessing value of rare disease treatments?
Rare Diseases
Luc Boileau, Chairman And Chief Executive Officer, INESSS
Capability building for RWE
RWE and Capability-building
Elena Panitti, Global Rwe Capability Building Lead, Novartis
Angelina Irizari Policarpio, Head of HEOR and RWE Field Communications Team, Eisai
Understanding access to MedTech innovations and the journey for companies
Pricing & Market Access
Marie Theres Schmidt, Director Market Access And Government Affairs, Edwards Lifesciences
Panel Discussion: Exploring the role of patient advocacy and engagement in rare diseases
Rare Diseases
Sheela Upadhyaya, Associate Director Highly Specialised Technologies, National Institute for Health and Care Excellence
Isabelle Ganache, Director of Bureau for Methodologies and Ethics, INESSS
Gundula Schneidewind, Head Ethics And Compliance, Europe And Canada, Takeda
Lara Pippo, Head Of Market Access, CSL Behring
Josie Godfrey, Director, JG Zebra Consulting
Shirin Rizzardo, Director of Specialty Medicines, Ministry of Health, British Columbia
Omar Dabbous, Vice President, Global Heor and Rwe, AveXis Inc
Harnessing real-world data and advanced analytics for value assessment
RWE and Capability-building
Bernard Hamelin, Global Head Of Medical Evidence Generation, Sanofi
Considerations in launching advanced diagnostics in Europe: Myriad’s myChoice HRD CDx
Pricing & Market Access
Benjamin Gannon, Vice President International Access, Policy And Advocacy, Myriad genetics
Karsten Berndt, International HTA Lead, Myriad Genetics GmbH
Chair’s Opening Remarks
Keynotes
Mary Lynne Van Poelgeest-Pomfret, President, President of the World Federation for Incontinence and Pelvic Pain - WFIP
Interview: Achieving greater cooperation between stakeholders to improve outcomes for the patient
Keynotes
Ryan Saadi, CEO, Tevogen Bio
Mary Lynne Van Poelgeest-Pomfret, President, President of the World Federation for Incontinence and Pelvic Pain - WFIP
Keynote Panel Discussion: Understanding what value truly means for pharma, payers, HTAs and patients and how we can bridge the gaps
Keynotes
Martin Schuchardt, Global Market Access Lead, Almirall
Saira Jan, Vice-President & Chief Pharmacy Officer, Blue Cross Blue Shield of New Jersey
Trevor Richter, Director, Pharmaceutical Reviews, CADTH
Nuriya Musina, Head Of Development, Federal State Budgetary Institution, The Center For Healthcare Quality Assessme, Ministry of Health Russian Federation
Mary Lynne Van Poelgeest-Pomfret, President, President of the World Federation for Incontinence and Pelvic Pain - WFIP
Mike Crosher, Managing Director, Chugai Pharma UK
Adam Kundzewicz, Global Head of Strategic Market Access Initiatives, Boehringer Ingelheim
Create your personal agenda –check the favourite icon
Chair’s opening remarks
Keynotes
Navin Joshi, Global Head of Pricing and Access Capabilities, GlaxoSmithKline
Outcomes-based healthcare: the role of value-based partnerships and RWE in improving access for rare disease patients
Keynotes
Mercedes Echauri, Head of Pricing, Value and Access , EUCAN, Takeda
Keynote Panel Discussion: Risk-sharing arrangements: Are they improving patient access to new medicines?
Keynotes
Oleksandra Oleshchuk, Head of Committee, EML Committee of Ukraine
Wim Goettsch, Special Hta-Advisor, Zorginstituut
Alexis Serlin, Head, Asia Cluster, Novartis
Valentin Dodonov, Head of Market Access, BIOCAD
Laura Guarga, Consultant of Pharmacoeconomic Department, CatSalut
Amer Omar, Head of Access & Reimbursement EMEA Neuroscience - Rare & Genetic Disease, Lupin
Navin Joshi, Global Head of Pricing and Access Capabilities, GlaxoSmithKline
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Panel Discussion: The impact of a Pandemic on Health Technology Assessment
HTA
Goedele Van Haasteren, Hta Specialist, Swiss Federal Office of Public Health
Michele de Guise, Scientific Vice-President, INESSS
Gustavo Saraiva Dos Anjos, Global Market Access Director For Biologics, GlaxoSmithKline
Mark Macgregor, Medical Director and Chair, New Drugs Committee, Scottish Medicines Consortium, Golden Jubilee National Hospital
Filippo Drago, Full Professor of Clinical Pharmacology, University of Catania
Helene Chevrou-Severac, HEOR Director, alexion
The evolution of risk sharing models for gene therapies and where to next?
Advanced Therapies
Gomathi Kaliappan, Health Systems Strategy Leader - Global Access, Roche
Exploring the world of “Implementation Science” and what it means for value
Value
Melvin Olson, Global Head Rwd Strategy And Innovation, Novartis Pharma
Pricing & Access Challenges in the absence of data – Gene therapies, Rare Diseases, & Oncology
Advanced Therapies
Chris Teale, Vice President Market Access, Ipsos MORI UK Ltd
Evolving access policy for cell and gene therapies
Advanced Therapies
Matt Slabbert, Global Head, Value & Access Policy, Bayer Pharmaceuticals
What is the role of AI in generating value?
Value
Andrea Mantovani, Former Market Access Executive, Independent
What to look out for from European HTAs: Latest insight
HTA
Paolo D'Agostino, EU Market Access Lead, Seqirus
Panel Discussion: How is patient centricity and RWE shaping access to cell & gene therapies?
Advanced Therapies
Paolo Morgese, EU Director Market Access & Member Relations, Alliance for Regenerative Medicine
Thomas Bols, Head of Government Affairs and Public Policy, EMEA & APAC, PTC Therapeutics
Nanxin (Nick) Li, Senior Director and Head, Health Economics and Outcomes Research (HEOR), uniQure
Daria Tolkacheva, Head of Health Economics, BIOCAD
Igor Rudychev, Vice President, Enterprise Analytics, Horizon Therapeutics
Ed Pezalla, Former Vice President, National Medical Director For Pharmaceutical Policy And Strategy, Aetna; a CVS Pharmacy Health Company
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
New times, old strategies: Government-Pharmaceutical Industry Agreements in Portugal
Government Affairs
Diogo Teixeira Pereira, Policy Analyst - Office for International Relations and Development, Infarmed
Introduction of new reimbursement regulation in Poland (medical fund) for highly innovative medicinal products
HTA
Dominik Dziurda, Head Of Health Services Division, AOTMiT
The role of government in market access: Understanding the wider context
Government Affairs
Bart Van Den Daele, Head Of External Affairs - Director Market Access, Gilead Sciences
Access and Health Technology Assessment in Brazil
HTA
Jonas Sertorio, Innovation and HTA Consultant, Ministry of Health - Brazil
Luciene Fontes Schluckebier Bonan, Innovation and HTA General Coordinator, Ministry of Health - Brazil
Insight from the NHS on best practice in negotiating contracts and price reductions
Payer Engagement & Strategy
Anusha Patel, High Costs Drugs Pharmacist and Regional Homecare Lead Pharmacist, Kettering General Hospital
Huge opportunities big challenges: Navigating the pharmaceuticals landscape in China
China & Developing Nations
Samuel Taylor, Emerging Markets Strategic Pricing Lead, Pfizer
Panel Discussion: What can be done to improve collaboration between patients and pharma?
Patient Advocacy
Dawn Torrence Ireland, President And Founder, C.H.E.R.U.B.S.
Clare Hague, Therapy Area Market Access Lead, Hematology, Janssen Pharmaceutical
Elizabeth Johnson, Lead Biologics Coordinator, Allergy Partners, P.A.
Nadia Bodkin, Founding member, Rare Advocacy Movement
Gina Ewy, Head Of Global Market Access, Hansa Biopharma
Edmund Lim, Executive Director, We CARE Journey
Ulrike Jacobi, Head Of External Affairs And Market Access, Amgen
Alfredo Gracia, Field Market Access Manager Spain, Baxter
Service changes to the Centers for Medicare and Medicaid and the implications for commercial payers
Payer Engagement & Strategy
Erin Mistry, SVP, Head of Payer Strategy, Gov’t Affairs and Trade Relations, CorMedix Inc
My Child Matters: Improving child cancer survival in the developing world
China & Developing Nations
Valerie Faillat, Head of Sanofi Espoir Foundation, Sanofi
Chair’s Opening Remarks
Keynotes
Lisette Kaskens, Senior Global Market Access Manager, Advanced Accelerator Applications
15 years: The impact and potential of biosimilars
Keynotes
Isabell Remus, Head Biopharmaceuticals Europe, Sandoz
Creating Operational and Cost Efficiencies in Long term Follow Up Studies
Keynotes
Alastair Macdonald, Senior Vice President Of Real World And Late Phase, Syneos Health
Keynote Panel Discussion: Accelerating Access to treatments for Rare Diseases
Keynotes
Diego Ardigo, Head of R&D, Global Rare Diseases, Chiesi Farmaceutici SpA
Lisette Kaskens, Senior Global Market Access Manager, Advanced Accelerator Applications
Michael Muller, Head Of Market Access, Western Europe, Sun Pharma
Detlev Parow, Head Pharmaceutical Department, DAK-Gesundheit
Kevin Rieger, Head Of Public And Governmental Affairs Dach, Ipsen Pharma Gmbh
Adam Plich, Managing Director, Plich Advisory
Anna Bucsics, Project Advisor, Mechanism of Coordinated Access to orphan medicinal products (MoCA)
Ines Alves, President, ANDO Portugal
Create your personal agenda –check the favourite icon
Understanding the role of AI based products to support medical decision-making and HTA analysis
Industry Showcase
Aletta de Beer, Product Owner Intensive Care, Pacmed
Experience in Multi-Payer Negotiations: Canada’s pan-Canadian Pharmaceutical Alliance
HTA & Payer Showcase
Dan McLean, Senior Manager, Pan-Canadian Pharmaceutical Alliance Office
Daniel Sperber, Senior Economist, Pan-Canadian Pharmaceutical Alliance Office
Market access opportunities and challenges for repurposed medicines during the Pandemic
Spotlight Session
Catarina Lopes Pereira, Global Market Access Manager, Medac
Exploring value-added medicines
Industry Showcase
Maja Sercic, Policy & Science Manager, Medicines for Europe
Key insight on the newly established HTA in Saudi Arabia
HTA & Payer Showcase
Mostafa Alabed, Health Economics Analyst, Evaluation and Impact Measurement Unit, Ministry Of Health - Kingdom Of Saudi Arabia
Pricing of Orphan Drugs: Pricing of orphan drugs in oncology and rare diseases
Spotlight Session
Mark Nuijten, Chief Executive Officer, A2M - Minerva
Value-based pricing for rare diseases in a changing US market environment
Industry Showcase
Diann Potestio, SVP Market Access, Reimbursement & Channel Strategy, Acadia Pharmaceuticals Inc.
Jenny Ebert, National Account Director, Ascendis Pharma
The evolution of pharmaceutical policies in Turkey
HTA & Payer Showcase
Kagan Atikeler, Market Access Manager, Sanofi-Aventis Turkey
Understanding the patient’s needs during the HTA journey
Spotlight Session
Jost Leemhuis, Head Of Safety Science, Roche
Evidence synthesis for HTA in Russia
Industry Showcase
Vladimir Mladov, HTA Manager, BIOCAD
Valeriia Sokolova, Health Economics Manager, BIOCAD
HTA journey in Ukraine: Value assessment of medicines
HTA & Payer Showcase
Oresta Piniazhko, Director, Hta Department, Ministry of Health of Ukraine
Market access for gene therapies in Germany
Spotlight Session
Axel Boehnke, Director Market Access EU North, PTC Therapeutics
Commercialization of digital therapeutics – pharma & startup partnerships
Industry Showcase
Ali Ciger, Commercial Director, Pain, Pfizer
Latest developments for HTA in Tunisia
HTA & Payer Showcase
Mouna Jameleddine Chtioui, Director of the Health Technology Assessment Department, INEAS - TUNISIA
How has COVID-19 shaped the digital landscape of the healthcare industry?
Spotlight Session
Rita Shorjian, Business Unit Director – Gulf Countries, Specialty, HCV & Oncology, AbbVie
Cross-collaboration amongst procurement agencies for the Nordics: Challenges and opportunities for industry
Industry Showcase
Jesper Bjerggren, Senior Market Access Manager, Teva Denmark
High-cost therapies in an era of cost containment
HTA & Payer Showcase
Laurene Redding, Former AVP Pharmaceutical Benefits and Innovation, Sun Life Financial
Utilising real world data to support value-based contracting: Reflections and opportunities
Spotlight Session
Birgit Holz, Global Head of Contracting Innovation, sanofi
Developing an evidence generation strategy to meet G-BA requirements
Evidence Strategy, Patient & Clinical Outcomes
Friedhelm Leverkus, Director Health Technology Assessment And Outcomes Research, Pfizer
Panel Discussion: Can industry afford affordable pricing strategies?
Affordability
Michael Schroter, Partner, VIOPAS Partners
David Alderson, Director, Cogentia Healthcare Consulting
Diane Munch, Head of Global Pricing, Patient & Health Impact, Pfizer
Charles-Etienne de Cidrac, Director Of Health Insurance, AXA
Jennifer Cain Birkmose, Vice President, Global Head Of Patient Access And Community Engagement, Swedish Orphan Biovitrum
Indranil Bagchi, Senior Vice President And Head Of Global Value And Access, Novartis
Kate Dion, Value Communications Lead, 3D Communications
Should technology evaluation take place before or after regulatory approval in Latin America?
Emerging Markets: Latin America
Maria Alejandra Blanc, Director - Regulatory Affairs – Region South America, AbbVie
The impact of COVID-19 on the access landscape in Latin America
Emerging Markets: Latin America
Marcela Junqueira, Oncology Market Access Director - Latin America, Janssen Pharmaceutical
Evidence generation for repurposed medicines
Evidence Strategy, Patient & Clinical Outcomes
Amer Omar, Head of Access & Reimbursement EMEA Neuroscience - Rare & Genetic Disease, Lupin
Latest insight on use of economic evidence for reimbursement in Latin America
Emerging Markets: Latin America
Andres Pichon Riviere, Executive Director And Director Of Health Technology Assessment And Economic Evaluations, I.E.C.S.
Leveraging technology to improve outcomes at a patient and clinical level
Evidence Strategy, Patient & Clinical Outcomes
Vijay Reddy, Global Market Access and Outcomes Research Leader - CCS Portfolio, GE Healthcare
Panel Discussion: Exploring how we can achieve the best outcomes when negotiating managed entry agreements
Managed Entry Agreements
David Watson, Executive Director, Economic, Health and Commercial Policy, ABPI
Marco Marchetti, Director Of The National Center For Health Technology Assessment, Istituto Superiore di Sanita
Inneke Van De Vijver, Strategic Advisor - Reimbursement Pharmaceuticals, R.I.Z.I.V. I.N.A.M.I. National Health Insurance Agency
Natasa Zibelnik, Global Head Of Market Access, EUSA Pharma
Douglas Foerster, Head Market Access, Santhera Pharmaceuticals
Kärt Veliste, Chief Specialist at Department of Medicines and Medical Devices, Haigekassa Estonia
Ayman Semaan, Head of Market Access, Algorithm
Latest insight on HTA in Egypt
Emerging Markets: Middle East
Zahraa Hassan, Pharmacoeconomics Unit, Egyptian drug authority
Asmaa Saad, Head of the Pharmacoeconomics unit, Egyptian drug authority
Launching a global clinical outcome-based study during a pandemic
Evidence Strategy, Patient & Clinical Outcomes
Erik Van Den Berg, Chief Executive Officer, A.M. Pharma
Understanding the reimbursement process in Israel
Emerging Markets: Middle East
Tomer Ben Zaken, Pricing And Alliance Manager, Takeda
How is digital health improving patient outcomes in diabetes and what HTA challenges do we face
Evidence Strategy, Patient & Clinical Outcomes
Nadeem Ashraf, Head of CardioMetabolism for Medical Affairs, UK & Ireland, Boehringer Ingelheim
Market Access framework and the impact of COVID-19 in the Middle East
Emerging Markets: Middle East
Sameh Abdou, Market Access & Strategic Alliance Manager Middle East & Africa, Abbott L.A
last published: 25/Feb/21 15:35 GMT
Password must meet the following requirements:
- At least one letter
- At least one capital letter
- At least one number
- Be at least 6 characters
